

May 4, 2016



Poxel Plans to Conduct Registered Initial Public Offering in the United States

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it plans to conduct a registered initial public offering in the United States. The timing, number of securities and price of the proposed offering have not yet been determined.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160504006069/en/>

Poxel SA

Jonae R. Barnes, +1 617-818-2985

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

or

Investor relations / Media - EU/US

MacDougall Biomedical Communications

Gretchen Schweitzer, + 49 89 2424 3494

or

Stephanie May, + 49 175 571 1562

smay@macbiocom.com

or

Investor relations / Media - France

NewCap

Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55

poxel@newcap.fr

Source: Poxel SA